Antistreptolysin o levels in patients with behcet’s disease

KARAKUZU, Ali; KARATAY, Saliha; UYANIK, Muhammed Hamidullah; UZKESER, HÜLYA; yildirim, kadir

Antistreptolysin o levels in patients with behcet’s disease

Hülya UZKESER, (Atatürk Üniversitesi, Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, Erzurum, Türkiye)

Saliha KARATAY, (Atatürk Üniversitesi, Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, Erzurum, Türkiye)

Kadir YILDIRIM, (Atatürk Üniversitesi, Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, Erzurum, Türkiye)

ALİ KARAKUZU, (Atatürk Üniversitesi, Tıp Fakültesi, Dermatoloji Anabilim Dalı, Erzurum, Türkiye)

Muhammed Hamidullah UYANIK (Atatürk Üniversitesi, Tıp Fakültesi, Mikrobiyoloji ve Klinik Mikrobiyoloji Anabilim Dalı, Erzurum, Türkiye)

Eurasian Journal of Medicine

12 0

Yıl: 2011 Cilt: 43 Sayı: 3 Sayfa Aralığı: 169 - 172 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Antistreptolysin o levels in patients with behcet’s disease

Öz:

Amaç: Behçet hastalığı multisistemik inflamatuar bir hastalıktır. Behçet hastalığının etiyolojisi henüz tam olarak belirlenememiştir. Bu çalışmada Behçet hastalarında antistreptolizin O (ASO) düzeylerinin incelenmesi amaçlanmıştır. Gereç ve Yöntem: Bu çalışmaya 30 Behçet hastası ve 30 sağlıklı kontrol katıldı. Her iki grupta eritrosit sedimantasyon hızı (ESH), serum C-reaktif protein (CRP) ve ASO düzeyleri ölçüldü. Bulgular: İki grup arasında demografik veriler açısından istatistiksel olarak anlamlı bir fark yoktu (p>0.05). Hasta ve kontrollerin ASO düzeyleri sırasıyla 288.4±145.7 ve 170.6±142.4 ng/ml idi. Behçet hastalarında ASO (p<0.01) ve ESH (p<0.05) değerleri sağlıklı kontrollerden anlamlı derecede yüksekti. Hasta ve kontrollerin serum CRP değerleri arasında anlamlı bir fark yoktu. ESH, serum CRP ve ASO değerleri arasında herhangi bir korelasyon bulunamadı. Sonuç: Bizim sonuçlarımıza göre Behçet hastalarında serum ASO seviyeleri yüksek olabilir. Behçet hastalarında ASO düzeyleri ve inflamasyon kaskadı arasındaki ilişkiyi belirlemek için yeni çalışmalara ihtiyaç duyulmaktadır.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Behçet hastalarında aso düzeyleri

Öz:

Objective: Behcet’s disease is a multisystem inflammatory disorder, and its etiology has not been defined clearly yet. In this study, we aimed to investigate the antistreptolysin O (ASO) levels of patients with Behcet’s disease. Materials and Methods: Thirty patients with Behcet’s disease and 30 healthy controls were enrolled in this study. We measured erythrocyte sedimentation rate (ESR), serum C-reactive protein (CRP), and ASO levels in both groups. Results: There was no statistically significant difference between the two groups with respect to demographic data (p>0.05). The ASO levels of the patients and the controls were 288.4±145.7 and 170.6±142.4 ng/ml, respectively. In the patients with Behcet’s disease, ASO (p<0.01) and ESR (p<0.05) values were significantly higher than in the healthy controls. There was no other significant difference in serum CRP levels between the patients and the controls. We could not find any correlation among ASO, CRP, and ESR values. Conclusion: Our results suggest that serum ASO levels may increase in patients with Behcet’s disease. Further studies are needed in order to define the relationship between ASO levels and inflammation status in Behcet’s disease.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Erdem F. MEFV Gene mutations in Behçet’s disease. EAJM 2007; 39: 130-3.
2. Kastner DL. Intermittent and periodic arthritic syndromes. In: Kopman WJ, ed. Arthritis and allied conditions: a textbook of rheumatology. 13th ed. Vol. 1. Baltimore: Williams&Wilkins 1997: pp. 1279-306.
3. Melikoglu MA, Melikoglu M. The influence of age on Behcet’s disease activity. EAJM 2008; 40: 68-71.
4. Ghate JV, Jorizzo JL. Behçet’s disease and complex aphthosis. J Am Acad Dermatol 1999; 40: 1-18.
5. Zierhut M, Mizuki N, Ohno S, et al. Immunology and functional genomics of Behçet’s disease. Cell Mol Life Sci 2003; 60: 1903-22.
6. Mizushima Y. Behcet’s disease. Curr Opin Rheumatol 1991; 3: 32-5.
7. Tsuchida M, Mineshita S, Okonogi H, et al. The role of an uncommon type of oral streptococcus sanguis in the etiology of behcet’s disease. Environ Health Prev Med 1997; 2: 59-63.
8. Isogai E, Ohno S, Kotake S, et al. Chemiluminescence of neutrophils from patients with Behçet’s disease and its correlation with an increased proportion of uncommon serotypes of Streptococcus sanguis in the oral flora. Arch Oral Biol 1990; 35: 43-8.
9. Hilário MO, Terreri MT. Rheumatic fever and post-streptococcal arthritis. Best Pract Res Clin Rheumatol 2002; 16: 481-94.
10. Hahn RG, Knox LM, Forman TA. Evaluation of poststreptococcal illness. Am Fam Physician 2005; 71: 1949-54.
11. International Study Group for Behçet’s Disease Criteria for diagnosis of Behçet’s disease. Lancet 1990; 335: 1078-80.
12. Evereklioglu C, Ozbek E, Cekmen M, et al. Plasma malondialdehyde levels in Behcet’s disease with or without ocular involvement. Adv Reprod 2000; 4: 231-6.
13. Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behçet’s disease: an update. Curr Opin Rheumatol 2011; 23: 24-31.
14. Oztas MO, Onder M, Gurer MA, Bukan N, Sancak B. Serum interleukin 18 and tumour necrosis factor-α levels are increased in Behçet’s disease. Clin Exp Dermatol 2005; 30: 61-3.
15. Oh SH, Lee KY, Lee JH, Bang D. Clinical manifestations associated with high titer of anti-streptolysin O in Behcet’s disease. Clin Rheumatol 2008; 27: 999-1003.
16. Kaneko F, Oyama N, Nishibu A. Streptococcal infection in the pathogenesis of Behçet’s disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J 1997; 38: 444-54.
17. Hirohata S, Oka H, Mizushima Y. Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behcet’s disease. Cell Immunol 1992; 140: 410-9.
18. Namba K, Ueno T, Okita M. Behcet’s disease and streptococcal infection. Jpn J Ophthalmol 1986; 30: 385-401.
19. Heymann RE, Ferraz MB, Quaresma MR, Golcalves CR, Atra E. The role of ambiental agents in Behcet’s disease. Rev Rhum Engl Ed 1995; 62: 343-8.
20. Alli N, Gur G, Yalcin B, Hayran M. Patient characteristics in Behçet disease: a retrospective analysis of 213 Turkish patients during 2001-4. Am J Clin Dermatol 2009; 10: 411-8.
21. Kökçam I, Naziroglu M. Effects of vitamin E supplementation on blood antioxidants levels in patients with Behçet’s disease. Clin Biochem 2002; 35: 633-9.
22. Calgüneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Celik I. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet’s disease. A randomized clinical trial. Arthritis Rheum 1996; 39: 2062-5.

APA	UZKESER H, KARATAY S, yildirim k, KARAKUZU A, UYANIK M (2011). Antistreptolysin o levels in patients with behcet’s disease. , 169 - 172.
Chicago	UZKESER HÜLYA,KARATAY Saliha,yildirim kadir,KARAKUZU Ali,UYANIK Muhammed Hamidullah Antistreptolysin o levels in patients with behcet’s disease. (2011): 169 - 172.
MLA	UZKESER HÜLYA,KARATAY Saliha,yildirim kadir,KARAKUZU Ali,UYANIK Muhammed Hamidullah Antistreptolysin o levels in patients with behcet’s disease. , 2011, ss.169 - 172.
AMA	UZKESER H,KARATAY S,yildirim k,KARAKUZU A,UYANIK M Antistreptolysin o levels in patients with behcet’s disease. . 2011; 169 - 172.
Vancouver	UZKESER H,KARATAY S,yildirim k,KARAKUZU A,UYANIK M Antistreptolysin o levels in patients with behcet’s disease. . 2011; 169 - 172.
IEEE	UZKESER H,KARATAY S,yildirim k,KARAKUZU A,UYANIK M "Antistreptolysin o levels in patients with behcet’s disease." , ss.169 - 172, 2011.
ISNAD	UZKESER, HÜLYA vd. "Antistreptolysin o levels in patients with behcet’s disease". (2011), 169-172.

APA	UZKESER H, KARATAY S, yildirim k, KARAKUZU A, UYANIK M (2011). Antistreptolysin o levels in patients with behcet’s disease. Eurasian Journal of Medicine, 43(3), 169 - 172.
Chicago	UZKESER HÜLYA,KARATAY Saliha,yildirim kadir,KARAKUZU Ali,UYANIK Muhammed Hamidullah Antistreptolysin o levels in patients with behcet’s disease. Eurasian Journal of Medicine 43, no.3 (2011): 169 - 172.
MLA	UZKESER HÜLYA,KARATAY Saliha,yildirim kadir,KARAKUZU Ali,UYANIK Muhammed Hamidullah Antistreptolysin o levels in patients with behcet’s disease. Eurasian Journal of Medicine, vol.43, no.3, 2011, ss.169 - 172.
AMA	UZKESER H,KARATAY S,yildirim k,KARAKUZU A,UYANIK M Antistreptolysin o levels in patients with behcet’s disease. Eurasian Journal of Medicine. 2011; 43(3): 169 - 172.
Vancouver	UZKESER H,KARATAY S,yildirim k,KARAKUZU A,UYANIK M Antistreptolysin o levels in patients with behcet’s disease. Eurasian Journal of Medicine. 2011; 43(3): 169 - 172.
IEEE	UZKESER H,KARATAY S,yildirim k,KARAKUZU A,UYANIK M "Antistreptolysin o levels in patients with behcet’s disease." Eurasian Journal of Medicine, 43, ss.169 - 172, 2011.
ISNAD	UZKESER, HÜLYA vd. "Antistreptolysin o levels in patients with behcet’s disease". Eurasian Journal of Medicine 43/3 (2011), 169-172.